Genprex, Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -9.40 | $0 | -$5M |
| 2026 Q1 | -14.08 | $0 | -$3M |
| 2025 Q4 | -25.30 | $0 | -$4M |
| 2025 Q3 | -110.00 | $0 | -$3M |
| 2025 Q2 | -187.00 | $0 | -$4M |
| 2025 Q1 | -286.00 | $0 | -$4M |
| 2024 Q4 |
| -462.00 |
| $0 |
| -$4M |
| 2024 Q3 | -1353.00 | $0 | -$1M |